According to the regulator, the so-called “Pharma Bro” hasn’t been complying with its investigation into whether his new company, Druglike, Inc, violates his ban from working in the pharmaceutical industry. A press release calls Druglike “a Web3 drug discovery software platform,” which definitely seems like something the world needs.
[Federal Trade Commission]















